Home / Resource Library / IBRUTINIB AND RITUXIMAB IS SUPERIOR TO IMMUNOCHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA DESPITE LOWER RATES OF MRD NEGATIVITY
IBRUTINIB AND RITUXIMAB IS SUPERIOR TO IMMUNOCHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA DESPITE LOWER RATES OF MRD NEGATIVITY